en · de · es · fr · pt
peptide-index.peptides6823.com › Data › Research And Regulatory Status — Research Overview

Research And Regulatory Status — Research Overview

By Editorial Desk · published 2025-11-11 · last reviewed 2025-12-11 · Data

This is a working overview of anti-doping analysis, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-12-11. Anything still debated is marked as such rather than presented as settled.

Research and Regulatory Status

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Aod-9604 at a glance

PropertyValueNotes
Primary research areaObesity and metabolic regulationStudied in cell, animal, and human models
Highest reported trial phasePhase IIPublic summaries describe mixed results
Common route in trialsSubcutaneous injectionTypical for peptide therapeutics
Regulatory example2013 Australian anti-doping reviewClassification was debated at the time
Approval statusNot approved as a human medicineStatus can change by jurisdiction

Regulation and Detection Context

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Related pages on this site

Identity and Molecular Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Notes from published material

I urge you and your administration to work in partnership with California and the other eight states that have legalized recreational marijuana for adult use in a way that will let us enforce our state laws that protect the public and our children while targeting the bad actors." Newsom responded to comments by Spicer that compared cannabis to opioids: "Unlike marijuana, opioids represent an addictive and harmful substance, and I would welcome your administration's focused efforts on tackling this particular public health crisis."

Air pollution in Hong Kong is considered a major problem. It became a concern soon after the start of the 2000s. According to the Environmental Protection Department (EPD), the major air pollutants in Hong Kong include nitrogen oxides (NOx), sulphur dioxide (SO2), respirable suspended particulates (RSP or PM10), fine suspended particulates (FSP or PM2.5), volatile organic compounds (VOC), carbon monoxide (CO), ozone and lead.

== Preparation == According to a recent study on cannabinoid concentration and stability in preparations of cannabis oil and tea, a boiling period of fifteen minutes was found to be sufficient in order to reach the highest concentrations of cannabinoids in tea solutions. However, preparation of cannabis oil in the study was found to ensure a higher stability of cannabinoids than that which was found in preparation of cannabis tea. To produce psychoactive effects, cannabis used in tea must first be decarboxylated. As with regular tea, spices are often added. Typically, the tea is allowed to simmer for 5–10 minutes.

Sources: en.wikipedia.org

Background from the literature

Flavins in general have fluorescent activity when unbound (proteins bound to flavin nucleic acid derivatives are called flavoproteins). This property can be utilized when examining protein binding, observing loss of fluorescent activity when put into the bound state. Oxidized flavins have high absorbances of about 450 nm, and fluoresce at about 515-520 nm.

RNA is transcribed with only four bases (adenine, cytosine, guanine and uracil), but these bases and attached sugars can be modified in numerous ways as the RNAs mature. Pseudouridine (Ψ), in which the linkage between uracil and ribose is changed from a C–N bond to a C–C bond, and ribothymidine (T) are found in various places (the most notable ones being in the TΨC loop of tRNA). Another notable modified base is hypoxanthine, a deaminated adenine base whose nucleoside is called inosine (I). Inosine plays a key role in the wobble hypothesis of the genetic code. There are more than 100 other naturally occurring modified nucleosides. The greatest structural diversity of modifications can be found in tRNA, while pseudouridine and nucleosides with 2'-O-methylribose often present in rRNA are the most common. The specific roles of many of these modifications in RNA are not fully understood. However, it is notable that, in ribosomal RNA, many of the post-transcriptional modifications occur in highly functional regions, such as the peptidyl transferase center and the subunit interface, implying that they are important for normal function.

Sanders also chaired the Senate Veterans' Affairs Committee from 2013 to 2015, the Senate Budget Committee from 2021 to 2023, and the Senate Health, Education, Labor and Pensions Committee from 2023 to 2025. He is the senior senator and dean of the Vermont congressional delegation. Sanders was a candidate for the Democratic presidential nomination in 2016 and 2020, finishing second both times. His 2016 campaign generated enthusiasm and funding from small-dollar donors, helping him win 23 primaries and caucuses. In 2020, his strong showing in early primaries and caucuses made him the front-runner in a large field of Democratic candidates. He became a close ally of Joe Biden after the 2020 primaries. Since Donald Trump's non-consecutive reelection as president of the United States in 2024, Sanders has vocally opposed Trump's second administration and what he describes as a right-wing oligarchy, organizing rallies against Trump and his allies, especially Elon Musk, as part of an effort to reshape the Democratic Party. Sanders is credited with influencing a leftward shift in the Democratic Party after his 2016 campaign. An advocate of progressive policies, he opposes neoliberalism and authoritarianism. He supports workers' self-management, universal and single-payer healthcare, paid parental leave, tuition-free tertiary education, a Green New Deal, and worker control of production through cooperatives, unions, and democratic public enterprises.

Sources: en.wikipedia.org

Frequently asked questions

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Why is AOD-9604 discussed in anti-doping?

It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.

What did human trials of AOD-9604 find?

Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Network